TEL AVIV, Israel and
FORT LAUDERDALE, Fla.,
Jan. 6, 2022 /PRNewswire/
-- Memic Innovative Surgery Ltd. (Memic), a medical device
company dedicated to transforming surgery with its proprietary
surgical robotic technology, today announced that HCA Florida
Healthcare's Kendall Regional Medical Center, AdventHealth
Celebration and The Women's Hospital at Jackson Memorial have
acquired the Hominis® Surgical System for use in single site,
natural orifice laparoscopic-assisted transvaginal benign
gynecological procedures including benign hysterectomy. Hominis is
the first and only FDA-authorized surgical robot that features
miniature humanoid-shaped arms, with shoulder, elbow, and wrist
joints that provide human level dexterity and 360-degree
articulation.
"It is essential that healthcare systems and clinicians continue
to invest in innovative and disruptive technology to offer superior
healthcare and optimal outcomes for patients," said Ricardo E. Estape, MD, a practicing gynecology
oncologist at Kendall Regional Medical Center and director of HCA
Healthcare's Institute for Gynecologic Oncology. "Kendall is one of
the busiest robotic surgery programs in South Florida, and we are proud to be among
the first in the U.S. to offer this novel system, allowing us to
perform minimally invasive gynecological procedures using the
transvaginal approach, which is known to offer less pain, lower
infection rates, faster recovery, and no visible scarring."
The Hominis System is designed to replicate the motions and
capabilities of a surgeon's arms. Multiple instruments can be
introduced to the body through a single portal and the 360-degree
articulation offers obstacle avoidance as well as optimal access
and working angles. Hominis requires a much smaller footprint and
costs significantly less than conventional robotic systems, making
it possible for more hospitals and ambulatory surgery centers to
acquire the system and offer more patients the benefits of less
invasive robotic surgery. Hominis was granted de novo marketing
authorization from the FDA in February
2021.
"As a leader in robotic surgery, we are always looking to bring
innovative and leading edge technology to our community to enhance
efficiency with surgical techniques and highlight our overall
commitment to whole person health care. This technology will allow
us to perform surgical techniques not feasible today and improve
the surgical experience for a wide range of patients," said
Doug Harcombe, CEO at AdventHealth
Celebration.
"As one of the region's most cutting-edge surgical centers, we
are excited to be adding new technology and surgical solutions that
will benefit our patients," said Joanne
Ruggiero, MSN, MA, NE-BC, interim CEO of Holtz Children's
Hospital/The Women's Hospital at Jackson Memorial. "We are proud to
be among the first in the country to offer this new scarless
surgery, and look forward to making an impact in the lives of our
South Florida patients."
"We are proud to partner with these leading healthcare providers
to empower surgeons with a better user experience and help them
better serve the thousands of women who undergo gynecologic surgery
each year," said Dvir Cohen,
co-founder and chief executive officer of Memic. "These sites
establish a strong foundation for expanding market adoption of
Hominis, including a leading robotic surgery center of excellence,
a 450-bed hospital owned by one of the largest U.S. hospital
systems, and a 1,550-bed nonprofit teaching hospital affiliated
with an acclaimed medical school. With their support, we are
expanding our commercial footprint to increase the reach of our
proprietary technology and have a positive impact on the
Florida region and elsewhere as we
work to expand adoption of Hominis worldwide."
About Memic
Memic, founded in 2013 and based in
Tel Aviv, Israel with a wholly
owned subsidiary based in Fort
Lauderdale, Florida, is a medical device company dedicated
to transforming surgery with its proprietary surgical robotic
technology. For more information, visit: https://memicmed.com/.
About MedTech Acquisition Corporation
MedTech Acquisition Corporation (Nasdaq: MTAC) is a blank check
company formed for the purpose of effecting a merger, share
exchange, asset acquisition, share purchase, reorganization or
similar business combination with one or more businesses or
entities. MedTech has stated a focus on the medical technology
industry in the United States and
other developed countries.]
Important Information about the Proposed Business Combination
and Where to Find It
In connection with the proposed merger with MedTech (the
"Business Combination"), Memic has filed with the SEC a
registration statement on Form F-4, which includes a preliminary
proxy statement/prospectus and intends to file a definitive proxy
statement/prospectus, and certain other related documents, which
will be both the proxy statement to be distributed to holders of
MedTech's shares of common stock in connection with the MedTech's
solicitation of proxies for the vote by MedTech's stockholders with
respect to the proposed business combination and other matters as
may be described in the registration statement, as well as the
prospectus relating to the securities to be issued in the proposed
transaction. MedTech's stockholders and other interested persons
are advised to read the preliminary proxy statement/prospectus
included in the registration statement and the amendments thereto
and the definitive proxy statement/prospectus, when available, as
well as other documents filed with the SEC in connection with the
proposed business combination, as these materials will contain
important information about the parties to the proposed business
combination agreement, Memic, MedTech and the proposed combined
company. After the registration statement is declared
effective, the definitive proxy statement/prospectus and other
relevant materials for the proposed business combination will be
mailed to stockholders of MedTech as of a record date to be
established for voting on the proposed business combination and
other matters as may be described in the registration statement.
Stockholders will also be able to obtain copies of the preliminary
proxy statement/prospectus, the definitive proxy
statement/prospectus, and other documents filed with the SEC that
will be incorporated by reference therein, without charge, once
available, at the SEC's website at www.sec.gov. In addition, the
documents filed by MedTech may be obtained by written request
to:
MedTech Acquisition Corporation
48 Maple Avenue
Greenwich, CT 06830
Participants in the Solicitation
Memic and MedTech and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from MedTech's stockholders in connection with the Business
Combination under the rules of the SEC. MedTech's stockholders,
Memic's shareholders and other interested persons may obtain,
without charge, more detailed information regarding the names,
affiliations and interests of directors and executive officers of
Memic and MedTech in MedTech's Annual Report on Form 10-K for the
fiscal year ended December 31, 2020,
as amended (File No.001-39813), or Memic's Form F-4, as amended
(File No. 333-259925) as applicable, as well as their other filings
with the SEC. Other information regarding persons who may, under
the rules of the SEC, be deemed the participants in the proxy
solicitation of MedTech's stockholders in connection with the
Business Combination and a description of their direct and indirect
interests, by security holdings or otherwise, are included in the
preliminary proxy statement/prospectus and will be contained in
other relevant materials to be filed with the SEC regarding the
Business Combination (if and when they become available). Free
copies of these documents can be obtained at the SEC's website at
www.sec.gov.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws with respect to
the proposed Business Combination between MedTech and Memic.
Forward-looking statements may be identified by the use of the
words such as "estimate," "plan," "project," "forecast," "intend,"
"expect," "anticipate," "believe," "seek," "strategy," "future,"
"opportunity," "may," "target," "should," "will," "would," "will
be," "will continue," "will likely result," or similar expressions
that predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements
include, but are not limited to, statements as to the expected
timing, completion and effects of the Business Combination, are
based on various assumptions, whether or not identified in this
press release, and on the current expectations of Memic's and
MedTech's management, are not predictions of actual performance,
and are subject to risks and uncertainties. These forward-looking
statements are subject to a number of risks and uncertainties,
including but not limited to: the risk that the Business
Combination may not be completed in a timely manner or at all; the
failure to satisfy the conditions to the consummation of the
Business Combination, including the failure to obtain approval of
the stockholders of MedTech; the inability to complete the
foregoing PIPE investment; the occurrence of any event, change or
other circumstance that could give rise to the termination of the
business combination agreement; the amount of redemption requests
made by MedTech's public stockholders; the effect of the
announcement or pendency of the Business Combination on Memic's
business; risks that the Business Combination disrupts current
plans and operations of Memic; challenges to Memic in the
manufacture, commercialization and marketing of its medical device
products; the availability, adoption and use of the Hominis®
Surgical System and the timing thereof; the ability to recognize
the anticipated benefits of the proposed transaction, which may be
affected by, among other things, the ability of Memic to grow,
manage growth profitably and retain its key employees; Memic's
estimates of its financial performance; changes in general economic
or political conditions; changes in the markets in which Memic
competes; the impact of natural disasters or health epidemics,
including the ongoing COVID-19 pandemic; legislative or regulatory
changes; industry risks related to the medical device and medical
technology industries; competition; conditions related to Memic's
operations in Israel; risks
related to data security and privacy; changes to accounting
principles and guidelines; potential litigation relating to the
proposed business combination; the ability to obtain and maintain
the listing of Memic's securities on the Nasdaq Capital Market; the
price of Memic's securities may be volatile; the ability to
implement business plans, and other expectations after the
completion of the Business Combination; and unexpected costs or
expenses. The foregoing list of factors is not exhaustive.
Foregoing factors and the other risks and uncertainties described
in the "Risk Factors" section of MedTech's Annual Report on Form
10-K for the fiscal year ended December 31,
2020, as amended (File No. 001-39813), and MedTech's
registration statement on Form S-1 (File No. 333-251037), and
Memic's registration statement on Form F-4, as amended (File No.
333-259925), and other documents should be carefully considered, if
and when filed by Memic or MedTech from time to time with SEC. If
any of these risks materialize or these assumptions prove
incorrect, actual events and results could differ materially from
those contained in the forward-looking statements. There may be
additional risks that neither Memic nor MedTech presently know or
that Memic and MedTech currently believe are immaterial that could
also cause actual events and results to differ. In addition,
forward-looking statements reflect Memic's and MedTech's
expectations, plans or forecasts of future events and views as of
the date they are made. Memic and MedTech anticipate that
subsequent events and developments will cause Memic's and MedTech's
assessments to change. While Memic and MedTech may elect to update
these forward-looking statements at some point in the future, Memic
and MedTech specifically disclaim any obligation to do so, unless
required by applicable law.
Any financial information or projections in this communication
are forward-looking statements that are based on assumptions that
are inherently subject to significant uncertainties and
contingencies, many of which are beyond Memic's and MedTech's
control. The inclusion of financial information or projections in
this communication should not be regarded as an indication that
Memic or MedTech, or their respective representatives and advisors,
considered or consider the information or projections to be a
reliable prediction of future events.
This communication is not intended to be all-inclusive or to
contain all the information that a person may desire in considering
an investment in MedTech and is not intended to form the basis of
an investment decision in MedTech. All subsequent written and oral
forward-looking statements concerning MedTech and Memic, the
Business Combination or other matters and attributable to MedTech
and Memic or any person acting on their behalf are expressly
qualified in their entirety by the cautionary statements above.
No Offer or Solicitation
This press release shall not constitute a solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the business combination. This press release shall
also not constitute an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of
securities in any states or jurisdictions in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of the Securities Act of 1933,
as amended.
Media Contact:
Lynn
Granito
Berry & Company Public Relations
lgranito@berrypr.com
973-818-3732
Investor Contact:
Greg
Chodaczek
Gilmartin Group
greg@gilmartinir.com
347-620-7010
View original
content:https://www.prnewswire.com/news-releases/memic-announces-adoption-of-hominis-surgical-system-at-three-leading-us-hospitals-in-q4-2021-301455253.html
SOURCE Memic